Russell Frank Company’s Anika Therapeutics ANIK Stock Holding History

Russell Frank Company’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$3.62M	Buy	81,047 +16,936	+26%	+$687K	0.01%	1524
2015 Q4	$2.49M	Buy	64,111 +14,304	+29%	+$547K	﹤0.01%	1705
2015 Q3	$1.58M	Buy	49,807 +17,907	+56%	+$624K	﹤0.01%	1983
2015 Q2	$1.05M	Buy	31,900 +12,720	+66%	+$454K	﹤0.01%	2287
2015 Q1	$790K	Hold	19,180	–	–	﹤0.01%	2255
2014 Q4	$780K	Buy	19,180 +17,637	+1,143%	+$689K	﹤0.01%	2262
2014 Q3	$57K	Sell	1,543 -26,701	-95%	-$1.15M	﹤0.01%	2719
2014 Q2	$1.31M	Buy	28,244 +7,723	+38%	+$343K	﹤0.01%	1947
2014 Q1	$843K	Sell	20,521 -1,365	-6%	-$50.7K	﹤0.01%	2156
2013 Q4	$719K	Sell	21,886 -11,992	-35%	-$370K	﹤0.01%	2206
2013 Q3	$812K	Buy	33,878 +33,807	+47,615%	+$759K	﹤0.01%	2281
2013 Q2	$1K	Buy	+71	New	+$1.02K	﹤0.01%	3209

Other funds holding ANIK

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

AAM

AMI Asset Management Los Angeles, California $1.57B AUM 19.49% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Russell Frank Company's ANIK Position: Q1 2016 in Review

Russell Frank Company increased its Anika Therapeutics (ANIK) stake by 26% in Q1 2016, buying an estimated $687K and bringing the position to 81,047 shares worth $3.62M. The position accounts for 0.01% of the portfolio, ranked #1524.

Russell Frank Company first reported a position in ANIK in Q2 2013 and has held it in 12 quarters since. 162 funds tracked by Wall St. Rank hold ANIK as of Q1 2016.

Russell Frank Company held 81,047 shares of Anika Therapeutics worth $3.62M as of Q1 2016.
Russell Frank Company bought 16,936 Anika Therapeutics shares in Q1 2016, an estimated $687K.
Anika Therapeutics made up 0.01% of Russell Frank Company's portfolio in Q1 2016, its #1524 holding.
Russell Frank Company first reported a position in Anika Therapeutics in Q2 2013 and has held it in 12 quarters since.
162 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.